explore -WSS

explore

author：knowledge 2025-08-25 05:56:52 - browse：5

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout Newsletter: The latest on Moderna, Apellis, and Merck

leisure time

WSS

3 medical device trends to watch in 2024

Federal weight loss drug coverage is 30 years out of date

Why health care costs have stayed mostly flat since 2010

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Hospitals owned by private equity see complications spike 25%

Videos point to link between seizures and unexplained toddler deaths

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Peter Hotez and the public health issue of online harassment

Antibiotic resistance and the global rise in human conflict

In Memoriam: Notable people who died in 2023

CRISPR gene editing developments we’re watching in 2024

George Santos makes 1st court appearance after pleading not guilty to 13 counts

White House finalizes ITC's import ban of latest Apple Watches

In Memoriam: Notable people who died in 2023

The FDA must approve intranasal treatments for anaphylaxis

BioMarin wins approval for gene therapy to treat hemophilia A

Goldman Sachs launches $650M fund for life science investments

hotspot

Grail spinoff by Illumina should end disastrous merger attempt

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

HCA sued by state AG for quality issues at Mission Health

Why psychiatrists like me stop taking insurance

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

The FDA must approve intranasal treatments for anaphylaxis

entertainment

hotspot

leisure time

hotspot